Results 211 to 220 of about 1,413,284 (292)
SURGELLA: A Scoping Review of Impella‐Assisted Hemodynamic Support in High‐Risk Non‐Cardiac Surgery
In selected patients with severe LV dysfunction, Impella‐supported non‐cardiac surgery may provide a temporary hemodynamic bridge to otherwise prohibitive procedures. Published evidence remains limited to a small number of highly selected cases, supporting technical feasibility rather than comparative benefit or generalizable safety.
Hussein Elghazaly +6 more
wiley +1 more source
New Insights Into Pediatric Pulmonary Hypertension From Bogota: Is Younger Always Better? [PDF]
Smith MA, Fineman JR.
europepmc +1 more source
Preventative practices and effects of the COVID-19 pandemic on caregivers of children with pediatric pulmonary hypertension. [PDF]
Nelson EJ +7 more
europepmc +1 more source
ABSTRACT Aim The aim of this study was to investigate the possible source of laboratory‐confirmed pertussis in infants under 6 months of age. Methods This nationwide prospective study was based on laboratory‐confirmed cases reported in the enhanced pertussis surveillance in Sweden from 2009 to 2015. The parents or carers of 345 infants were interviewed
Bernice Aronsson +4 more
wiley +1 more source
Pediatric Pulmonary Hypertension is Associated With Increased Circulating Levels of BMP 7 and CHIP. [PDF]
Kirkpatrick EC +6 more
europepmc +1 more source
Moyamoya disease associated with pediatric pulmonary hypertension-a case report. [PDF]
Krämer J +5 more
europepmc +1 more source
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke +9 more
wiley +1 more source
Usefulness and importance of echocardiography in the diagnosis of pediatric pulmonary hypertension. [PDF]
Choi HJ.
europepmc +1 more source
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova +15 more
wiley +1 more source

